Immuno-Oncology

Robert Dreicer, MD, highlights the current state of immunotherapy in urothelial cancer and ongoing research poised to offer more information on how to broaden its effects.

Toni Choueiri, MD, discusses the use of checkpoint inhibitors to treat patients with sarcomatoid carcinoma.

Jyoti Malhotra, MD, MPH, discusses a phase I multicenter trial of PD-1 blockade with pembrolizumab with concurrent chemoradiation in patients with locally advanced, unresectable non–small cell lung cancer.

Investigators see potential in adding targeted therapy to dual immunotherapy for intermediate- and poor-risk patients with renal cell carcinoma. In the phase III COSMIC-313 trial, investigators aim to evaluate cabozantinib, nivolumab, and ipilimumab in patients with untreated advanced RCC.

Timothy M. Kuzel, MD, FACP, discusses the use of immunotherapy as a targeted approach to treating cancer.

Switch maintenance treatment with pembrolizumab improved progression-free survival in patients with metastatic urothelial cancer who have stable disease following frontline platinum-based chemotherapy.